Eiger BioPharmaceuticals

Eiger BioPharmaceuticals, Inc. engages in the development and commercialization of foundational therapies for Hepatitis Delta Virus. It is also developing avexitide as a treatment for Post-Bariatric Hypoglycemia. The company was founded by David A. Cory and Glenn S. Jeffrey on November 6, 2008 and is headquartered in Palo Alto, CA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Eiger BioPharmaceuticals, Inc. operates as a biopharmaceutical company, which focuses on the development of innovative therapies for rare metabolic diseases. It is also developing avexitide as a treatment for Post-Bariatric Hypoglycemia. The company was founded by David A. Cory and Glenn S. Jeffrey on November 6, 2008 and is headquartered in Palo Alto, CA.

Did you lose money on investments in Eiger BioPharmaceuticals, Inc.? If so, please visit Eiger BioPharmaceuticals, Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com to discuss your rights.

EIGER BIOPHARMACEUTICALS, INC. (EIGR) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Eiger BioPharmaceuticals, Inc. (EIGR)

NEW YORK, Nov. 10, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) between March 10, 2021 and October 4, 2022, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed.

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Eiger BioPharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - EIGR

SAN DIEGO--(BUSINESS WIRE)---- $EIGR #COVID19--Eiger Biopharmaceuticals, Inc. Misled Shareholders Regarding the Viability of its Product Candidate Designed to Treat COVID-19

Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Eiger Biopharmaceutials, Inc. (EIGR)

NEW YORK--(BUSINESS WIRE)-- #BioPharmaceuticals--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) between March 10, 2021 and October 4, 2022, both dates inclusive (the “Class Period”).

EQUITY ALERT: Rosen Law Firm Encourages Eiger BioPharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – EIGR

PALO ALTO, Calif. , Nov. 8, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today announced that members of its management team will participate in the following upcoming investor conferences: Stifel 2022 Healthcare Conference Date & Time: Tuesday, November 15, 2022 at 10:55 a.m.

Eiger BioPharmaceuticals to Participate in Upcoming Investor Conferences

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR ) Q3 2022 Results Conference Call November 3, 2022 4:30 PM ET Company Participants Sarah Mathieson - Senior Vice President, Corporate Affairs David Cory - President and CEO Sri Ryali - Chief Financial Officer Eldon Mayer - Chief Commercial Officer Ingrid Choong - Senior Vice President, Clinical Development Colin Hislop - Senior Vice President, Clinical & Development Operations Colleen Craig - Vice President, Metabolic Diseases Conference Call Participants Maury Raycroft - Jefferies Charlie Moore - Baird Bert Hazlett - BTIG Farhana Sakloth - Ladenburg Operator Welcome to the Eiger BioPharmaceuticals Third Quarter 2022 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode.

Eiger BioPharmaceuticals, Inc. (EIGR) Q3 2022 Earnings Call Transcript

Eiger BioPharma (EIGR) delivered earnings and revenue surprises of -12.73% and 2.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Eiger BioPharmaceuticals (EIGR) Reports Q3 Loss, Tops Revenue Estimates

Phase 3 HDV D-LIVR (lonafarnib-based regimens) Study Topline Data in December Phase 3 HDV LIMT-2 (peginterferon lambda) Study Activating Sites and Enrolling Patients Phase 3 Congenital Hyperinsulinism Avant (avexitide) Program Initiated Strong Cash Position: $121.0 Million in Cash, Cash Equivalents, and Total Investments PALO ALTO, Calif. , Nov. 3, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today reported financial results for third quarter 2022 and provided a business update.

Eiger BioPharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

NEW YORK , Oct. 27, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Flowserve Corporation (""Eiger" or the "Company") (NASDAQ: EIGR). Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Eiger BioPharmaceuticals, Inc. - EIGR

-  Live Conference Call and Webcast at 4:30 PM ET  - PALO ALTO, Calif. , Oct. 24, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today announced that it will host a conference call on Thursday, November 3, 2022 at 4:30 PM ET to discuss its third quarter 2022 financial results and provide a business update.

Eiger BioPharmaceuticals to Host Conference Call for Third Quarter 2022 Financial Results and Business Update on Thursday, November 3

PALO ALTO, Calif. , Oct. 11, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today announced that David Cory, President and CEO, will present a company overview at the H.C.

Eiger BioPharmaceuticals to Present at the H.C. Wainwright Third Annual Hepatitis B Virus (HBV) Virtual Conference

New York, New York--(Newsfile Corp. - October 8, 2022) - Pomerantz LLP is investigating claims on behalf of investors of Flowserve Corporation (""Eiger" or the "Company") (NASDAQ: EIGR). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Eiger and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Eiger BioPharmaceuticals, Inc. - EIGR

Shares of Eiger BioPharmaceuticals Inc. EIGR, -1.20% tumbled 20.4% in premarket trading on Wednesday after the company said it will not pursue emergency authorization of its experimental treatment for mild and moderate COVID-19 infections. It had asked the Food and Drug Administration to consider an EUA application based on data from the Together trial, a Phase 3 study that has assessed 11 possible treatments for COVID-19 that is being conducted in Brazil and Canada.

Eiger's stock falls 20% after telling investors it won't seek FDA authorization for COVID-19 drug

PALO ALTO, Calif. , Oct. 5, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today announced that, following feedback from the U.S. Food and Drug Administration (FDA), the company will not submit an emergency use authorization (EUA) application of peginterferon lambda for the treatment of patients with mild-to-moderate COVID-19.

Eiger BioPharmaceuticals Provides Update on Plans for Emergency Use Authorization Application Following FDA Feedback

PALO ALTO, Calif. , Sept. 22, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today announced that David Cory, President and CEO, will present a company overview at the 2022 Ladenburg Thalmann Healthcare Conference on Thursday, September 29, 2022 at 1:00 PM ET in New York City.

Eiger BioPharmaceuticals to Present at the 2022 Ladenburg Thalmann Healthcare Conference

PALO ALTO, Calif. , Sept. 6, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today provided an update on the status of its planned request for emergency use authorization (EUA) of peginterferon lambda for the treatment of patients with mild-to-moderate COVID-19 based on its most recent communications with the U.S. Food and Drug Administration (FDA).

Eiger BioPharmaceuticals Provides Update on Status of Planned Peginterferon Lambda COVID-19 Emergency Use Authorization Application

PALO ALTO, Calif. , Sept. 1, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today announced that members of its management team will participate in the following upcoming investor conferences: Citi's 17th Annual BioPharma Conference Date: Thursday, September 8, 2022 Location: Boston, MA Format: One-on-one meetings H.C.

Eiger BioPharmaceuticals to Participate in Three Upcoming Investor Conferences

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Sarah Mathieson - SVP, Corporate Affairs David Cory - President & CEO Ingrid Choong - SVP-Clinical Development Eldon Mayer - Chief Commercial Officer Sriram Ryali - CFO Colleen Craig - VP-Metabolic Diseases Conference Call Participants Maurice Raycroft - Jefferies Robert Hazlett - BTIG Michael Higgins - Ladenburg Thalmann Operator [Starts Abruptly] and business update conference call. At this times, all participants are in a listen-only mode.

Eiger BioPharmaceuticals, Inc. (EIGR) CEO David Cory on Q2 2022 Results - Earnings Call Transcript

Eiger BioPharma (EIGR) delivered earnings and revenue surprises of 28.17% and 94.81%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Eiger BioPharmaceuticals (EIGR) Reports Q2 Loss, Tops Revenue Estimates

Active Dialogue with FDA on Potential Peginterferon Lambda COVID-19 EUA Application Phase 3 HDV D-LIVR (lonafarnib) Study Topline Data Planned by Year End Phase 3 Congenital Hyperinsulinism AVANT (avexitide) Program Initiated Approval of Zokinvy in Europe; Partnership with AnGes in Japan Strong Cash Position: $141.8M Cash, Cash Equivalents, and Total Investments PALO ALTO, Calif. , Aug. 4, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) infection and other serious diseases, today reported financial results for second quarter 2022 and provided a business update.

Eiger BioPharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

-  Live Conference Call and Webcast at 4:30 PM ET  - PALO ALTO, Calif. , July 28, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today announced that it will host a conference call on Thursday, August 4, 2022 at 4:30 PM ET to discuss its second quarter 2022 financial results and provide a business update.

Eiger BioPharmaceuticals to Host Conference Call for Second Quarter 2022 Financial Results and Business Update on Thursday, August 4

European Commission granted marketing authorization for Zokinvy (lonafarnib) for the treatment of patients with progeria on July 20, 2022. Results from the phase 3 D-LIVR study using Lonafarnib for the treatment of patients with Hepatitis Delta Virus are expected by end of 2022.

Eiger BioPharmaceuticals: Undervalued Biotech With End Of 2022 Catalyst

First and only treatment approved in Europe to treat Hutchinson-Gilford progeria syndrome and processing-deficient progeroid laminopathies1 Extended life by an average of 4.3 years in children and young adults with HGPS2 Now approved for use in 30 European countries, following approval in the U.S in 20201 PALO ALTO, Calif. , July 20, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus and other serious diseases announced today the European Commission (EC) has granted marketing authorization for Zokinvy® (lonafarnib), a first-in-class breakthrough therapy for children and young adults with Hutchinson-Gilford progeria syndrome (HGPS) and processing-deficient progeroid laminopathies (PL).

Eiger Receives European Approval for Zokinvy® (lonafarnib) for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies

PALO ALTO, Calif. , July 18, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious diseases, today announced the appointment of Lisa Kelly-Croswell to its Board of Directors.

Eiger Appoints Senior Human Resources and Organizational Executive Lisa Kelly-Croswell to Board of Directors

PALO ALTO, Calif. , June 27, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious diseases, today announced data presented at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2022 that took place June 22-26 in London, United Kingdom.

Eiger BioPharmaceuticals Announces Results from Multiple Presentations at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2022

News for Eiger BioPharmaceuticals Stock (EIGR)